Antibiotic susceptibility of Francisella tularensis subsp. holarctica strains isolated from tularaemia patients in France between 2006 and 2016
Open Access
- 14 December 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (3) , 687-691
Abstract
To determine the in vitro susceptibility to 18 antibiotics of human strains of Francisella tularensis isolated in France between 2006 and 2016, to check the absence of acquired resistance and to evaluate potential therapeutic alternatives. Fifty-nine clinically unrelated F. tularensis subsp. holarctica strains identified at the French National Reference Centre for Francisella as belonging to the phylogenetic subclade B.FTNF002-00 were used. MICs were determined in CAMHB medium supplemented with 2% PolyViteX®, using the CLSI broth microdilution method. All strains were susceptible to fluoroquinolones (ofloxacin, ciprofloxacin, levofloxacin and moxifloxacin; MIC range: 0.016–0.25 mg/L), aminoglycosides (gentamicin and tobramycin; MIC range: ≤0.03–0.25 mg/L), doxycycline (MIC range: 0.125–0.25 mg/L) and chloramphenicol (MIC range: 0.5–2 mg/L). The erythromycin MIC range (0.5–2 mg/L) confirmed that all isolates belonged to biovar I of F. tularensis subsp. holarctica. Azithromycin and telithromycin displayed lower MIC ranges (0.25–1 and 0.03–0.5 mg/L, respectively). The tigecycline MIC range (0.25–1 mg/L) was slightly higher than that of doxycycline. All strains were resistant to ampicillin, meropenem, daptomycin, clindamycin and linezolid. F. tularensis strains isolated in France remain susceptible to antibiotic classes recommended for tularaemia treatment. Because fluoroquinolones display the lowest MIC90, have bactericidal activity and have lower therapeutic failure rates compared with doxycycline, they may be advocated as first-line treatment of mild cases of tularaemia, predominant in Europe. MIC data also indicate that azithromycin or telithromycin may be possible therapeutic options against biovar I strains from Western Europe in case of contraindication to first-line antibiotics.Keywords
This publication has 17 references indexed in Scilit:
- Antibiotic susceptibility in vitro of Francisella tularensis subsp. holarctica isolates from GermanyJournal of Antimicrobial Chemotherapy, 2017
- Clonality of erythromycin resistance inFrancisella tularensisJournal of Antimicrobial Chemotherapy, 2016
- Tularaemia: clinical aspects in EuropeThe Lancet Infectious Diseases, 2016
- 10 years of surveillance of human tularaemia in FranceEurosurveillance, 2014
- Characterisation of a new group of Francisella tularensis subsp. holarctica in Switzerland with altered antimicrobial susceptibilities, 1996 to 2013Eurosurveillance, 2014
- Phylogeography ofFrancisella tularensissubsp.holarctica, EuropeEmerging Infectious Diseases, 2012
- Human Tularemia in France, 2006-2010Clinical Infectious Diseases, 2011
- Phylogeography of Francisella tularensis ssp. holarctica in FranceLetters in Applied Microbiology, 2010
- Phylogeography of Francisella tularensis : Global Expansion of a Highly Fit CloneJournal of Bacteriology, 2009
- Genomic Deletion Marking an Emerging Subclone of Francisella tularensis subsp. holarctica in France and the Iberian PeninsulaApplied and Environmental Microbiology, 2007